CD8A and head and neck squamous cell carcinoma: Most noteworthy, we found that mice implanted with the LY2 HNSCC cell line and treated with ENI had a reduction in CD8 T cells expressing CD69, an early activation marker and IL-2, a survival cytokine (Fig. 1F).